Sign In
Buy BXRX
$0.0218
+0 (+0%)
At Close: May 28, 2024
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:25pm, Friday, 03'rd Jul 2020
Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00am, Friday, 03'rd Jul 2020
MALVERN, Pa., July 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care...
Baudax Bio (NASDAQ:BXRX) Shares Down 6.4%
02:46am, Sunday, 21'st Jun 2020
Baudax Bio (NASDAQ:BXRX) shares fell 6.4% during mid-day trading on Friday . The stock traded as low as $3.79 and last traded at $3.79, 515,967 shares changed hands during mid-day trading. A decline o
MALVERN, Pa., June 15, 2020 -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the commercial launch.
Baudax Bio Secures $50 Million Credit Facility
11:00am, Monday, 01'st Jun 2020
Baudax Bio, Inc. (BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit facility of up to $50 million from funds managed by Ma
Baudax Bio, Inc. (NASDAQ:BXRX) Insiders Increased Their Holdings
10:12am, Monday, 18'th May 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv
06:02pm, Monday, 11'th May 2020
Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on
Monday.
HIGHLIGHTS
Baudax Bio Reports First Quarter 2020 Financial Results
11:00am, Friday, 08'th May 2020
ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers.
Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020
11:00am, Tuesday, 05'th May 2020
MALVERN, Pa., May 05, 2020 -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced a virtual poster.
Baudax Bio Announces Change in Location of its 2020 Annual Meeting of Shareholders to its Corporate Headquarters
08:05pm, Friday, 01'st May 2020
Baudax Bio, Inc. (BXRX) (the “Company”), a pharmaceutical company focused on therapeutics for acute care settings, today announced that due to the emerging health impact of the coronavirus pandemi
Healthcare Investor Steven Boyd Is Gobbling Up These 3 Stocks
02:02pm, Wednesday, 29'th Apr 2020
With the market’s trajectory remaining unknown, hedge fund manager Steven Boyd believes that one industry in particular still houses exciting opportunities: the healthcare sector. Compared to the br
MALVERN, Pa., April 23, 2020 -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced two virtual poster.
Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain
12:00pm, Tuesday, 07'th Apr 2020
ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing Full Commercial Launch Expected to Commence by June 2020 MALVERN, Pa.,.
Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:40pm, Friday, 03'rd Apr 2020
Baudax Bio, Inc. (BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducem
Baudax Bio Announces Closing of $25 Million Public Offering of Securities
03:35pm, Thursday, 26'th Mar 2020
Baudax Bio, Inc. (“Baudax” or the “Company”) (BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of the previously announced public of
